Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
GNI Group ( (JP:2160) ) has shared an update.
GNI Group’s U.S.-based consolidated subsidiary Cullgen Inc. will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, one of the industry’s most prominent investor events that convenes global healthcare executives and institutional investors. Alongside this appearance, Cullgen has published an updated corporate presentation outlining key pipeline progress, including plans to start a Phase 2 clinical trial in the second quarter of 2026 for its novel non-opioid pain candidate CG001419 and the advancement of a new targeted protein degrader program for inflammatory diseases into IND-enabling studies, developments that underscore the group’s push to expand its clinical-stage portfolio and raise its profile with international investors.
The most recent analyst rating on (JP:2160) stock is a Hold with a Yen2443.00 price target. To see the full list of analyst forecasts on GNI Group stock, see the JP:2160 Stock Forecast page.
More about GNI Group
GNI Group Ltd. is a Japan-listed biopharmaceutical group (TSE Growth: 2160) engaged in drug discovery and development through subsidiaries including Cullgen Inc., which focuses on targeted protein degradation and other innovative therapeutics aimed at areas such as pain management and inflammatory diseases.
Average Trading Volume: 1,248,638
Technical Sentiment Signal: Hold
Current Market Cap: Yen127.3B
Learn more about 2160 stock on TipRanks’ Stock Analysis page.